Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Arcus Biosciences by Quarter
Arcus Biosciences — Research and development (R&D) expense ($M) ($M)
Gilead Sciences Arcus Biosciences: $113M in Q2 2026, down 18.7% from a year earlier.
Latest, Q2 2026
113
Period ended Jun 30, 2026
Change on a year earlier
-18.7%
139 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below
Where the Q2 2026 figure comes from
Source: Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗
Reported in Arcus Biosciences (RCUS) Form 10-Q / 10-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Gilead Sciences Arcus Biosciences ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus-rd-exp
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.